OncoMatch/Clinical Trials/NCT05868395
Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma
Is NCT05868395 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Polatuzumab, bendamustin und rituximab for mantle-cell lymphoma.
Treatment: Polatuzumab, bendamustin und rituximab — Polatuzumab, bendamustine and rituximab in patients with relapsed/ refractory mantle cell lymphoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemotherapy — first line
r/r MCL patients following standard first line chemotherapy
Must have received: BTK inhibitor (ibrutinib)
who have received at least one prior regimen including ibrutinib
Cannot have received: bendamustine (bendamustine)
Exception: response duration must have been > 1 year
If the participant has received prior bendamustine, response duration must have been > 1 year
Cannot have received: monoclonal antibody
Exception: within 4 weeks or 5 half-lives before cycle 1 day 1
Prior use of any MAb, radioimmunoconjugate, or antibody-drug conjugate (ADC) within 4 weeks or 5 half-lives before cycle 1 day 1
Cannot have received: investigational agent
Exception: within 28 days prior to initiation of study treatment
Use of any investigational agent within 28 days prior to initiation of study treatment
Cannot have received: radiotherapy
Exception: within 2 weeks prior to cycle 1 day 1
Treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational agent for the purposes of treating cancer within 2 weeks prior to cycle 1 day
Cannot have received: chemotherapy
Exception: within 2 weeks prior to cycle 1 day 1
Treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational agent for the purposes of treating cancer within 2 weeks prior to cycle 1 day
Cannot have received: immunotherapy
Exception: within 2 weeks prior to cycle 1 day 1
Treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational agent for the purposes of treating cancer within 2 weeks prior to cycle 1 day
Cannot have received: immunosuppressive therapy
Exception: within 2 weeks prior to cycle 1 day 1
Treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational agent for the purposes of treating cancer within 2 weeks prior to cycle 1 day
Cannot have received: autologous stem cell transplant
Exception: within 100 days prior to cycle 1 day 1
Autologous stem cell transplant (SCT) within 100 days prior to cycle 1 day 1
Cannot have received: allogeneic stem cell transplant
Prior allogeneic SCT
Lab requirements
Blood counts
adequate hematological function unless inadequate function is due to underlying disease
Kidney function
adequate renal function unless inadequate function is due to underlying disease
Liver function
adequate hepatic function unless inadequate function is due to underlying disease
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify